Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal

Executive Summary

Xtandi sales declined 11% in the first quarter due to an increase in the use of patient assistance programs, but demand grew 13%, which management said reflects the underlying strength of the prostate cancer drug.

You may also be interested in...



Get Ready For The Return Of The Mega-Merger, Leerink Says

Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.

J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide

Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.

Pfizer Poised To PROSPER From Xtandi In Expanded Indication

Pfizer needed good news from the Phase III PROSPER trial testing Xtandi in non-metastatic prostate cancer patients to show investors the Medivation deal was worth the cost. It got what it was hoping for.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel